Synopsis: India’s largest life sciences commercialisation company has simultaneously watched its full-year net profit slip 1.4 percent to Rs. 401 crore, as acquisition-related depreciation, a TCPA litigation settlement provision, and integration expenses absorbed the topline gains.
A Bengaluru-based digital-first life sciences commercialisation company came into focus on April 29, 2026, after its board approved audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. The filing, submitted under SEBI Listing Regulations, disclosed one of the company’s strongest quarterly revenue prints alongside a full-year earnings number that, despite a 23.6 percent revenue jump, ended marginally below the prior year.
With a market capitalization of approximately Rs. 12,051.09 crore, the shares of Indegene Limited were trading at approximately Rs. 500.25 per share, up 0.97 percent from its previous close of Rs. 495.45 apiece. It is trading at a P/E of approximately 30x.
Q4 FY26 Performance
Consolidated revenue from operations for Q4 FY26 was Rs. 1,003.4 crore, up 32.8 percent year-on-year from Rs. 755.6 crore in Q4 FY25. The Enterprise Commercial Solutions segment contributed Rs. 719.3 crore in the quarter, while Enterprise Medical Solutions added Rs. 253.7 crore and the remaining Others segment contributed Rs. 30.4 crore.
Q4 consolidated PAT came in at Rs. 79.7 crore, against Rs. 117.6 crore in Q4 FY25, a decline of 32.2 percent. Three factors drove this compression: depreciation and amortisation charges rose to Rs. 41.8 crore (from Rs. 20.7 crore in Q4 FY25), primarily on account of intangible assets identified in the BioPharm purchase price allocation; employee benefit expenses jumped to Rs. 632.4 crore from Rs. 485.1 crore; and the company recorded a Rs. 20.3 crore exceptional item in Q4 representing a provision for a class action litigation settlement in the United States, where Indegene Inc. had been named as a defendant in a complaint alleging violations of the Telephone Consumer Protection Act.
The settlement framework provides for a maximum payout of USD 4.72 million (approximately Rs. 41.7 crore), with actual outflow contingent on valid claims by class members.
Full Year Snapshot
FY26 tells a story that is unusual for a growth company of Indegene’s profile. Consolidated revenue from operations grew 23.6 percent to Rs. 3,510.5 crore from Rs. 2,839.3 crore in FY25. Total income for the year reached Rs. 3,582.5 crore. Yet consolidated net profit for FY26 was Rs. 401.1 crore, compared to Rs. 406.7 crore in FY25, a decline of 1.4 percent. Basic consolidated EPS slipped from Rs. 17.15 to Rs. 16.72, a drop of 2.5 percent despite 23.6 percent revenue growth.
The arithmetic of this divergence is straightforward. Depreciation and amortisation expense for FY26 was Rs. 126.4 crore, against Rs. 80.2 crore in FY25, a 57.6 percent increase driven by intangible assets acquired in the BioPharm deal. Employee costs rose to Rs. 2,197.7 crore from Rs. 1,815.2 crore. Other expenses climbed to Rs. 693.8 crore from Rs. 489.8 crore reflecting marketing agency overhead and integration costs within the enlarged commercial solutions business. On top of these, the Rs. 20.3 crore TCPA provision was recognised as an exceptional item, making it the first time the company has disclosed an exceptional item since listing.
The BioPharm Acquisition
The single most consequential event of FY26 was the October 1, 2025 acquisition of BioPharm Parent Holdings Inc., a full-service US healthcare marketing agency formerly part of Omnicom Health Group. The total consideration was USD 99.77 million (approximately Rs. 882.1 crore), including deferred and contingent earnout consideration.
BioPharm contributed to revenues from October 2025 onwards, adding approximately Rs. 354 crore to FY26 revenues in the second half of the year. Management’s pro-forma estimate suggests that had the acquisition occurred on April 1, 2025, full-year consolidated revenue would have been Rs. 3,834.3 crore and pre-tax profit Rs. 636.9 crore.
The purchase price allocation identified intangible assets of Rs. 215.8 crore and allocated goodwill of Rs. 642.9 crore, the latter representing expected workforce synergies and value of the acquired client base. This goodwill amount sits on the consolidated balance sheet and will be tested annually for impairment. Total consolidated goodwill as of March 31, 2026 stands at Rs. 1,134.3 crore, sharply up from Rs. 356.5 crore a year ago.
Two smaller acquisitions also closed during the year. Warn & Co Limited, a UK-based transformation consulting firm, was acquired in October 2025 for GBP 3.91 million. Cake Kommunikations Holdings GmbH, a DACH-region healthcare advertising agency with operations in Germany, Austria, and Switzerland, was acquired in January 2026 for EUR 8.9 million extending the group’s European marketing services footprint.
Segment Analysis
The Enterprise Commercial Solutions segment covering promotional, digital, and omnichannel marketing services for pharma and biotech clients generated Rs. 2,460.5 crore in FY26, up 27.2 percent from Rs. 1,934.8 crore. This segment now accounts for approximately 70 percent of consolidated revenues. Enterprise Medical Solutions, covering medical affairs, regulatory writing, and clinical documentation, grew 17.1 percent to Rs. 939.8 crore.
Segment results (EBIT-level) show that Enterprise Commercial Solutions delivered Rs. 449.2 crore in profit, up 14 percent YoY, while Enterprise Medical Solutions contributed Rs. 243.5 crore. The commercial segment’s margins, however, have come under pressure as BioPharm’s lower-margin agency model gets integrated; a dynamic management will need to be addressed through cross-selling and operational leverage over FY27 and FY28.
Dividend
The board also approved a final dividend of Rs. 2.25 per equity share (face value Rs. 2), up from Rs. 2.00 per share in FY25, subject to shareholder approval at the ensuing AGM. If approved, the total cash outflow on account of dividend will be approximately Rs. 54.2 crore.
Business Overview
Indegene Limited, incorporated in 1998 and listed in May 2024 following an IPO at Rs. 452 per share, is a digital-first life sciences commercialisation company headquartered in Bengaluru. The company provides commercial, medical, regulatory, and analytics services to pharmaceutical, biotech, and medical device companies across the US, Europe, and Asia. Its consolidated subsidiary network spans 30 entities across the US, UK, Canada, Germany, Austria, Switzerland, Japan, Mexico, Ireland, China, Singapore, Spain, and India.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
The post Indegene Revenue Surges 24% in FY26; Net Profit Dips to ₹401 Cr Amid Acquisition Costs appeared first on Trade Brains.